PR Newswire
22 Aug 2022, 17:30 GMT+10
Albert Wu, MD, PhD, a recognized advocate of using stem cell therapy to treat eye conditions, will advise company's development of ocular tissue rejuvenation therapeutics
MOUNTAIN VIEW, Calif., Aug. 22, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that Albert Wu, MD, PhD, will oversee its development of ophthalmic therapeutic products as an advisor to the company.
A board-certified ophthalmologist and fellowship-trained specialist in oculoplastic and orbital surgery, Wu's academic work has focused on developing treatments for vision loss and eye disease.
At Turn Bio, he will shepherd work on TRN-004, a formulation to rejuvenate ocular tissues, including corneal, limbal and conjunctival epithelial cells, as well as corneal endothelial cells. Preclinical results show the formulation reduces inflammation, oxidative stress, and cell senescence.
TRN-004 is a tailored protein cocktail to rejuvenate targeted cells in the eye. It is produced using Turn Bio's unique mRNA-based ERA (Epigenetic Reprogramming of Aging) platform.
"Albert's life mission is to transform ophthalmology by making regenerative medicine an accepted treatment for people worldwide suffering from diseases of the eye," said Anja Krammer, the company's CEO. "His vision and experience will help us redefine how eye doctors treat age-related vision conditions for which no real cure exists."
Wu has nearly two decades of experience with ophthalmology and cellular biology. He has been honored by the National Institutes of Health, American Society of Ophthalmic Plastic and Reconstructive Surgery, Icahn School of Medicine at Mount Sinai, the University of Washington and Yale University.
"Our work has the potential to revolutionize eye care to preserve patients' vision and, ultimately, restore it," said Wu. "The ability to produce cell rejuvenation therapies and deliver them with pinpoint accuracy offers enormous promise to millions of people around the world whose sight has been compromised by untreatable conditions."
Wu received his bachelor's degree in Molecular Biophysics and Biochemistry from Yale University, his medical degree and doctoral degree in Molecular and Cellular Biology from the University of Washington. He has co-authored 55 articles on his research discoveries and has contributed to textbooks on ophthalmology and ophthalmologic oncology. He is a frequent presenter at national and international medical conferences.
ABOUT TURN BIOTECHNOLOGIES
Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level. The company's proprietary mRNA platform technology, ERA, restores optimal gene expression by combatting the effects of aging in the epigenome. This restores the cells' ability to prevent or treat disease, heal or regenerate tissue and fight incurable chronic diseases.
The company is currently completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, as well as developing therapies for ophthalmology, osteo-arthritis and the muscular system. For more information, see www.turn.bio.
FOR MORE INFORMATION, CONTACT:
Jim Martinez, rightstorygroup
[email protected] or (312) 543-9026
SOURCE Turn Biotechnologies, Inc.
Get a daily dose of Singapore Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Singapore Star.
More InformationWASHINGTON, DC - U.S. President Donald Trump how bowed to pro-Israel elements in his administration and Congress, announcing that the...
ZURICH, Switzerland: The Swiss National Bank (SNB) lowered its key interest rate to zero percent on June 19 to respond to falling inflation,...
WASHINGTON, D.C.: The U.S. government is preparing to revise its influential dietary advice, with a significant shift: dropping the...
ZURICH, Switzerland: The U.S. saw an extraordinary rise in wealth last year, with more than 1,000 people crossing into millionaire...
THE HAGUE, Netherlands: The city that prides itself on being a beacon of peace and justice—home to institutions like the International...
BUENOS AIRES, Argentina: Since taking office in December 2023, Argentine President Javier Milei has implemented sweeping austerity...
WASHINGTON, D.C.: As the global weight-loss market explodes, drugmakers are now racing to solve a less visible problem: protecting...
HAYWARD, California: In a significant step toward its commercial debut, Amazon-owned Zoox has unveiled its first factory dedicated...
SAO PAULO, Brazil: Brazil is taking confident steps to restore its dominance in global poultry exports after declaring its commercial...
NEW YORK, New YorK - U.S. stocks closed mixed on Friday, with gains and losses modest, as investors and traders weighed up the escalation...
WASHINGTON, D.C.: Retail sales dropped sharply in May as consumer spending slowed after a strong start to the year, primarily due to...
WASHINGTON, D.C.: Mitsubishi Motors is the latest automaker to raise prices in the United States, joining a growing list of car companies...